Takeda Pharmaceutical (TAK) Total Liabilities (2017 - 2026)

Takeda Pharmaceutical's Total Liabilities history runs 10 years deep, the most recent figure standing at $49.0 billion for Q1 2026.

• In Q1 2026, Total Liabilities rose 2.15% year-over-year to $49.0 billion; the TTM figure through Mar 2026 stood at $49.0 billion (up 2.15% YoY), while the FY2026 annual figure was $51.0 billion, up 6.26% from the prior year.
• Total Liabilities was $49.0 billion for Q1 2026 at Takeda Pharmaceutical, down from $50.5 billion in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $64.5 billion in Q1 2022 to a low of $47.9 billion in Q1 2025.
• Historically, Total Liabilities has averaged $53.4 billion across 5 years, with a median of $51.9 billion in 2022.
• The sharpest annual moves came in 2022 and 2026: Total Liabilities fell 19.96% in 2022, then climbed 2.15% in 2026.
• A 5-year view of Total Liabilities shows it stood at $51.9 billion in 2022, then fell by 2.44% to $50.6 billion in 2023, then declined by 0.08% to $50.6 billion in 2024, then dropped by 0.22% to $50.5 billion in 2025, then slipped by 2.96% to $49.0 billion in 2026.
• The last three Total Liabilities figures came in at $49.0 billion (Q1 2026), $50.5 billion (Q4 2025), and $49.8 billion (Q3 2025), per Business Quant data.